Swedish firm Orphan Biovitrum (Sobi) has obtained orphan drug designation in Switzerland for its long-acting haemophilia drug candidate Elocta (rFVIIIFc) to treat patients with haemophilia A.

Haemophilia is an inherited condition that regulates the blood’s ability to clot and the most common type of the condition is haemophilia A, where people lack clotting factor FVIII.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Elocta is a long-acting recombinant factor VIII Fc fusion protein product candidate for patients with haemophilia A.

"It would offer our customers increased flexibility for cargo capability, while still being able to accommodate passenger."

Elocta is the European trade name for rFVIIIFc and is also called Eloctate (Antihemophilic Factor [Recombinant], Fc Fusion Protein) in the US, Canada, Australia, and Japan, where it received approval to treat haemophilia A. Marketing authorisation application for Elocta is currently under review by the European Medicines Agency.

Sobi and Biogen collaborated on the development and commercialisation of Elocta or Eloctate or rFVIIIFc for haemophilia A.

Under the deal, Sobi will have final development and commercialisation rights for rFVIIIFc in its territory, including Europe, North Africa, Russia and certain Middle Eastern markets.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Biogen will take responsibility for the development of Elocta, and will hold manufacturing and commercialisation rights in North America and all other regions across the globe except Sobi territory.

Sobi produces products for haemophilia, inflammation and genetic diseases.

The company, along with various partner companies, markets a portfolio of speciality and orphan drugs in Europe, the Middle East, Russia and North Africa.